Novartis AG (NVS)

$89.49

-0.35 (-0.39%)
Rating:
Recommendation:
Buy
Symbol NVS
Price $89.49
Beta 0.493
Volume Avg. 2.00M
Market Cap 193.093B
Shares () -
52 Week Range 74.09-94.26
1y Target Est -
DCF Unlevered NVS DCF ->
DCF Levered NVS LDCF ->
ROE 34.47% Strong Buy
ROA 18.40% Buy
Operating Margin -
Debt / Equity 94.65% Buy
P/E 9.23 Strong Buy
P/B 3.19 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NVS news


Joseph Jimenez
Healthcare
Drug Manufacturers—General
New York Stock Exchange

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.